Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current assets
Cash and cash equivalents	$ 210,596	$ 4,304
Prepaid expenses and other current assets	6,804	44
Other Assets		331
Security deposits		158
Total current assets	217,400	4,837
Property, plant and equipment, net	27	42
Security deposits	255
Total assets	217,682	4,879
Current liabilities
Accrued clinical drug supplies and trial costs	2,485	1,013
Accounts payable and accrued expenses	3,810	1,391
Notes payable		11,040
Warrant liability		966
Total current liabilities	6,295	14,410
Royalty purchase liability	41,667
Total liabilities	47,962	14,410
Preferred Stock, Convertible and Redeemable:
Total Preferred Stock, Convertible and Redeemable		113,939
Stockholders' equity (deficit)
Common stock - $0.001 par value, 200,000,000 shares authorized, 31,413,208 shares issued and outstanding at December 31, 2013; 155,864,851 shares authorized, 1,469,798 shares issued and outstanding at December 31, 2012	31	1
Additional paid-in capital	352,739
Deficit accumulated during development stage	(183,050)	(126,471)
Total stockholders' equity (deficit)	169,720	(123,470)
Total liabilities and stockholders' equity (deficit)	217,682	4,879
Series A
Preferred Stock, Convertible and Redeemable:
Total Preferred Stock, Convertible and Redeemable		69,471
Series A-1
Preferred Stock, Convertible and Redeemable:
Total Preferred Stock, Convertible and Redeemable		8,460
Series B
Preferred Stock, Convertible and Redeemable:
Total Preferred Stock, Convertible and Redeemable		35,456
Series B-1
Preferred Stock, Convertible and Redeemable:
Total Preferred Stock, Convertible and Redeemable		552
Junior Series A Convertible Preferred Stock
Stockholders' equity (deficit)
Preferred Stock		3,000
Preferred stock
Stockholders' equity (deficit)
Preferred Stock